A systematic review and meta-analysis of gene therapy in animal models of cerebral glioma

Citation for published version:

Digital Object Identifier (DOI):
10.1002/ebm2.6

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Peer reviewed version

Published In:
Evidence-based Preclinical Medicine

Publisher Rights Statement:
© 2015 The Authors. Evidence-based Preclinical Medicine Published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
A systematic review and meta-analysis of gene therapy in animal models of cerebral glioma: why did promise not translate to human therapy?

T. C. Hirst,1 H. M. Vesterinen,1 S. Conlin,1 K. J. Egan,1 A. Antonic,2 A. Lawson McLean,1 M. R. Macleod,3* R. Grant,3 P. M. Brennan,3 E. S. Sena1,2 and I. R. Whittle3

1Centre for Clinical Brain Sciences, Chancellors Building, University of Edinburgh, Edinburgh, UK 2Florey Neuroscience and Mental Health Institute, University of Melbourne, Victoria, Australia and 3Division of Clinical Neurosciences, University of Edinburgh, Western General Hospital, Edinburgh, UK

(2015) Evidence-based Preclinical Medicine 1, 1, 21–33, e00006, DOI: 10.1002/ebm2.6

ABSTRACT

Background: The development of therapeutics is often characterized by promising animal research that fails to translate into clinical efficacy; this holds for the development of gene therapy in glioma. We tested the hypothesis that this is because of limitations in the internal and external validity of studies reporting the use of gene therapy in experimental glioma.

Method: We systematically identified studies testing gene therapy in rodent glioma models by searching three online databases. The number of animals treated and median survival were extracted and studies graded using a quality checklist. We calculated median survival ratios and used random effects meta-analysis to estimate efficacy. We explored effects of study design and quality and searched for evidence of publication bias.

Results: We identified 193 publications using gene therapy in experimental glioma, including 6,366 animals. Overall, gene therapy improved median survival by a factor of 1.60 (95% CI 1.53–1.67). Study quality was low and the type of gene therapy did not account for differences in outcome. Study design characteristics accounted for a significant proportion of between-study heterogeneity. We observed similar findings in a data subset limited to the most common gene therapy.

Conclusion: As the dysregulation of key molecular pathways is characteristic of gliomas, gene therapy remains a promising treatment for glioma. Nevertheless, we have identified areas for improvement in conduct and reporting of studies, and we provide a basis for sample size calculations. Further work should focus on genes of interest in paradigms recapitulating human disease. This might improve the translation of such therapies into the clinic.

Keywords: systematic review, rodent models, glioma, gene therapy

FUNDING INFORMATION

Funded by the National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs).

Data availability: The authors confirm that all data underlying the findings are fully available without restriction. Raw data from studies included in the review and meta-analysis and publication bias results are available from the Dryad Digital Repository: http://doi.org/10.5061/dryad.bs8c4.

Introduction

The prognosis for patients with malignant glioma remains poor despite extensive experimental and clinical research.1 The most effective treatments tested in randomized controlled trials are glioblastoma chemotherapy (temozolomide) and bevacizumab.2 However, the limited efficacy of these treatments and the high recurrence rate following surgical resection have made glioma a prime target for novel therapeutics.3–5 Although gliomas are heterogeneous,6,7 advances in our understanding of the biology of gliomas have made them one of the most attractive diseases for targeted therapy.8–10 Recently, gene therapy has emerged as a promising treatment for glioma.11–13 This is due to the ability of gene therapy to correct abnormalities in key molecular pathways and to have a prolonged effect compared to chemotherapy.14–16 As a result, gene therapy has been extensively tested in experimental glioma models.17–22

However, studies testing gene therapy in experimental glioma are characterized by low study quality.23–26 This holds for studies reporting the use of gene therapy in animal models of cerebral glioma.27–29 Despite the promise of preclinical research,27–30 clinical trials of gene therapy have failed to show significant improvement in median survival.23–26 This is despite advances in delivery vectors31 and expression systems.32–34 This has led to a growing consensus that the translation of preclinical research to the clinic is poor.35–38 A recent systematic review of the clinical trials of gene therapy for glioma highlighted this problem, reporting that none of the randomized controlled trials of gene therapy led to a significant improvement in median survival.39 Thus, while preclinical research is promising,35–38 clinical trials have failed to yield meaningful benefits to patients.40–42

A key reason for the failure of preclinical research to translate to clinical efficacy is the discrepancy between the efficacy of gene therapy in preclinical and clinical trials.43–45 Thus, the purpose of our review was to test the hypothesis that the discrepancy between preclinical and clinical trials of gene therapy stems from limitations in the internal and external validity of studies reporting the use of gene therapy in experimental glioma. To do this, we performed a systematic review and meta-analysis of the studies that have tested gene therapy in rodent glioma models. We compared the results to those of clinical trials of gene therapy for glioma. Here, we present the results of our systematic review and meta-analysis and discuss the implications for future research.
controlled trials show a median survival of 14 months from
diagnosis, only marginal progress from the 9 months
median survival reported in clinical trials in the 1970s. This
poor prognosis reflects the highly invasive nature of mali-
gnant glioma and resistance to conventional anticancer treat-
ments. These tumours are proliferating lesions within an
otherwise quiescent organ and rarely metastasize, rather
progressing by diffuse invasion along white matter tracts
and by inducing oedema through generation of abnormal
blood vessels. Therefore they are an ideal target for local
treatment of efficacy of gene therapy in malignant glioma
after therapy. Several previous studies on experimental
ing small efficacious studies versus small ineffective
models of neurological disease have demonstrated the flaws
in other smaller clinical studies.

Several narrative reviews have described the promise of
gene therapy in malignant glioma; however, thus far
this promise has remained unfulfilled in the clinical setting.
Three complementary reasons for this failure have been
proposed: (1) efficacy is overstated in animal models, (2)
potential efficacy is understated in human clinical trials or
(3) animal models simply do not recapitulate the human
disease with sufficient fidelity in order to be useful. Systematic
review and meta-analysis can provide a more transparent
and objective summary of a field of research than narrative
reviews; they allow assessment of scientific rigour of
included studies using standard instruments. In addition,
stratified meta-analysis can explore the impact of independ-
ent study design variables (termed external validity) on
reported outcome; assess the prevalence and impact of
measures to reduce bias such as randomization, blinded out-
come assessment and sample size calculations (termed
internal validity); and can provide evidence of possible pub-
lished criteria and required studies to report: (1) a single
form of gene therapy, (2) a rat or mouse model of glioma, (3)
the glial cell line used, (4) intracerebral implantation of
the tumour, (5) median survival data reported within the
text or which could be calculated from Kaplan Meier survival
graphs and (6) the number of animals in the control and
treatment group(s). We defined a single gene therapy as
the use of a single vector containing either one or multiple
genes. To improve the sensitivity of identification of
relevant studies, each publication identified in the electronic
search was assessed individually against the inclusion and
exclusion criteria by two of four independent reviewers
(SC, ALM, TCH and MRM), with differences resolved by
discussion.

METHODOLOGICAL QUALITY

A 9-item quality checklist was adapted from the CAMAR-
ADEs (Collaborative Approach to Meta-Analysis and
Review of Animal Data in Experimental Studies) published
criteria and the glioma-specific score previously described
by our group. The checklist comprised (1) publication in a
peer-reviewed journal and the reporting of (2) the number of
tumour cells implanted, (3) randomized allocation of
tumour-bearing animals to treatment and control groups,
(4) blinded assessment of outcome, (5) a sample size calcu-
lation, (6) compliance with animal welfare regulations, (7)
a potential conflict of interest, (8) the number of animals ori-
ginally inoculated with tumour cells and (9) an explanation of
any treated animals excluded from survival analysis. While
not detailed as a quality checklist item in the study protocol,
in response to comments raised in review we have also con-
sidered whether the study provided evidence of successful
transduction and gene expression in vitro, and whether the
study provided evidence of infection, replication and
expression in the tumour in vivo.

METHODOLOGICAL QUALITY

A 9-item quality checklist was adapted from the CAMAR-
ADEs (Collaborative Approach to Meta-Analysis and
Review of Animal Data in Experimental Studies) published
criteria and the glioma-specific score previously described
by our group. The checklist comprised (1) publication in a
peer-reviewed journal and the reporting of (2) the number of
tumour cells implanted, (3) randomized allocation of
tumour-bearing animals to treatment and control groups,
(4) blinded assessment of outcome, (5) a sample size calcu-
lation, (6) compliance with animal welfare regulations, (7)
a potential conflict of interest, (8) the number of animals ori-
ginally inoculated with tumour cells and (9) an explanation of
any treated animals excluded from survival analysis. While
not detailed as a quality checklist item in the study protocol,
in response to comments raised in review we have also con-
sidered whether the study provided evidence of successful
transduction and gene expression in vitro, and whether the
study provided evidence of infection, replication and
expression in the tumour in vivo.
DATA EXTRACTION AND ANALYSIS

We extracted data for median survival time, the number of animals in both the treatment and control groups and details of study design characteristics (the gene therapy used, animal species, co-morbidities, tumour cell line, gene therapy vector, route of administration, number of doses, delay to treatment and method of determining survival and presentation of data (i.e. textual or graphical)). We grouped gene therapy into broad categories of angiogenesis, DNA repair, immunomodulation, oncolytic and “other”. We calculated an effect size for each comparison by dividing the median survival in the treatment group by the median survival in the control group in the median survival in the control group to give a median survival ratio.

A preliminary stratification identified that studies that used a prodrug in the treatment group (to activate the gene therapy) but not in the control group were associated with significantly larger effects than those using prodrug in both groups, suggesting biological activity of the prodrug alone. Therefore, studies using a prodrug were only included where the same prodrug was also used in the control group. Some studies reported more than one control group. We considered the most appropriate control group to be the one that was most similar to the treatment group, while offering no functional gene therapy, according to a hierarchy that prodrug with non-functioning vector was preferred to prodrug with saline, which was preferred to prodrug only. Where a prodrug was not used, the hierarchy was non-functioning vector in preference to saline-only in preference to no treatment. For studies in which more than 50% of animals survived till the end of the experiment, we used the last time point at which survival was reported to give a conservative measure of median survival.

Individual study effect sizes were weighted by the number of animals for that comparison, as there is no inherent measure of variance available for median survival data. Where a control group served more than one treatment group we corrected the weighting of the study by dividing the number of animals in the control group by the number of treatment groups served. Effect sizes were calculated on log-transformed data using the random effects model of Dersimonian and Laird, as we expected significant heterogeneity between experiments. We estimated the standard error of the summary estimates from the inter-study variance (as described previously).

We used stratified meta-analysis to estimate the significance of differences between groups of studies by partitioning heterogeneity and using the \(\chi^2\) distribution with \(n - 1\) degrees of freedom (where \(n\) is the number of strata). We performed stratified analyses on the complete dataset that included all gene therapies reported. We also performed analyses on a more homogenous subset of data that consisted of only the most common gene therapy—herpes simplex virus thymidine kinase activated by ganciclovir (GCV). To allow for multiple comparisons (we performed 26 comparisons; 15 on the complete dataset and 11 on the thymidine kinase subset of data) we adjusted our significance level to \(p < 0.0019\) using Bonferroni correction for 26 tests of statistical significance in the same dataset. We used funnel plotting, Egger regression and “trim and fill” to assess for the presence of publication bias.

To estimate the statistical power of a typical experiment, we calculated the median observed values for median survival in the control and treatment groups and the median numbers in each group and used the “stpower exponential” functional in Stata. Data extracted from studies included in the review and the results of meta-analysis and publication bias assessment are available from the Dryad Digital Repository: http://doi.org/10.5061/dryad.bs8c4.

Results

We identified 3,860 publications, of which 208 met our inclusion criteria (Figure 1; Appendix S1, Supporting Information). Of these, 193 publications reported data suitable for meta-analysis; these described 427 comparisons using 6,366 animals (Appendices S1 and S2).

Overall, 127 different gene therapies were tested. A total of 101 used a single gene and 26 used two genes in a single vector (Appendices S2 and S3). Thymidine kinase was the most common gene therapy (61 comparisons, given as a single gene therapy in 49) followed by IL-4 (23 comparisons), IL-2 (21 comparisons) and tumour necrosis factor-related apoptosis inducing ligand (TRAIL, 18 comparisons). Across all 127 gene therapies there was a significant improvement in the median survival time (survival ratio 1.60, 95% CI 1.53—1.67), and there was significant between-study heterogeneity (\(\chi^2 = 1,522; df = 426, p < 0.0019; I^2 = 72\%\)). While

---

Figure 1. Study selection summary.
the approaches to gene therapy were diverse, the broad category of gene therapy used did not account for a significant proportion of the observed heterogeneity (Figure 2).

**RISK OF BIAS**

The median number of quality checklist items reported was three of a possible nine (interquartile range (IQR) 3–4; Appendix S4); 193 (100%) publications were in peer-reviewed journals, 170 (88.1%) reported the number of tumour cells implanted, 23 (12.4%) randomly allocated animals to group, 7 (3.6%) blinded the assessment of outcome, 133 (68.9%) had a statement of compliance with animal welfare regulations, 15 (7.8%) had a statement of a potential conflict of interest, 24 (12.4%) reported the number of animals originally inoculated with the tumour and 41 (21.1%) gave an explanation of any treated animals excluded from the survival analysis. A total of 139 studies (72.0%) provided evidence of successful transduction and gene expression in vitro and 90 (46.6%) provided evidence of infection, replication or expression in the tumour in vivo. No publication reported a sample size calculation and the median number of animals in each of the control and treatment groups was eight (IQR 6–10). In 90 publications it was reported that animals were killed when they manifested signs reflecting disease of a certain severity (rather than allowing them to die of their disease), and in the remainder of studies the circumstances of death (euthanasia or spontaneous) were not reported.

The aggregate number of quality checklist items scored or the reporting of randomized group allocation did not account for between-study heterogeneity (Figure 3A). Only seven publications (9/427 comparisons) reported the blinded assessment of outcome, too few to allow further analysis. We did not identify any differences in treatment effects between studies that reported survival data within the text and those where data were extracted from a graph.

Bias introduced by an excess of small, imprecise studies was suggested with asymmetry in the funnel plot (Figure 3B) and Egger regression (11.3 ± 0.301; t = 11.3, p < 0.001; Figure 3C) but not using “trim and fill”.

**INFLUENCE OF FACTORS RELATING TO GENE DELIVERY**

The method of gene delivery (molecules, viruses, cells or virus-producing cells) had a significant impact on the
reported effect size. Cells and virus-producing cells were associated with the largest treatment effects ($\chi^2 = 24.1$, df = 3, p < 0.0019; Figure 4A). Furthermore, the selection of viral delivery system accounted for a significant proportion of between-study heterogeneity ($\chi^2 = 53.0$, df = 3, p < 0.0019). The greatest estimates of effect were observed where retroviruses and adeno-associated viruses were used. Similarly, selection of cellular delivery system also accounted for significant between-study heterogeneity ($\chi^2 = 56.2$, df = 5, p < 0.0019). Bone marrow-derived stem cells and neural stem cells were associated with the largest effect sizes.

Several gene therapy paradigms were reported that usually included the concomitant use of a prodrug; 67 comparisons reported such combinations, for instance thymidine kinase with GCV, cytosine deaminase (CD) with 5-fluorocystine (5-FC). Furthermore, these same gene therapies were sometimes used without the appropriate prodrug (35 comparisons). Gene therapies using a prodrug were associated with an increased effect size if that prodrug was used (1.90; 95% CI 1.67–2.14, n = 67) when compared with the same gene therapies where no prodrug was used (1.27; 1.14–1.41, n = 35; $\chi^2 = 45.6$, df = 1, p < 0.0019) with median survival ratio being 50% higher (95% CI 35–65%). A further 17 comparisons involved prodrugs not usually associated with the gene therapy used (i.e. prodrug used alongside that gene in fewer than 50% of comparisons; e.g. interferon with 5-FC, tumour necrosis factor with GCV).

Figure 4. Features of gene therapy delivery. A. The vector used to deliver gene therapy accounted for a significant proportion of heterogeneity in the complete dataset, and there was evidence of differing efficacy between different cellular and virus vector paradigms (p < 0.0019). The grey band represents global 95% confidence intervals (CIs); plots represent mean ± 95% CI and the diamond represents a measure of number of comparisons within each stratum. The dotted line represents the level of neutral treatment effect. B. The number of doses accounted for between-study heterogeneity (p < 0.0019), the largest effect seen with five doses. The grey band represents global 95% CIs; columns represent mean ± 95% CI and column width a measure of number of comparisons within each stratum. The solid line represents the level of neutral treatment effect. C. The route of gene therapy delivery accounted for heterogeneity, with the largest efficacy associated with intra-arterial and intraperitoneal systemic delivery, and ipsilateral and contralateral intracranial therapy (p < 0.0019). There was no observed difference in efficacy between intracranial and systemic administration. The grey band represents global 95% CIs; columns represent mean ± 95% CI and the diamond represents a measure of number of comparisons within each stratum. The dotted line represents the level of neutral treatment effect. D. The delay to treatment (where “0” refers to the day of tumour inoculation, “>0” therapy initiation post-tumour inoculation and “<0” therapy initiated before tumour inoculation) accounted for heterogeneity (p < 0.0019), with therapy given concomitantly with tumour inoculation giving the greatest efficacy. The grey band represents global 95% CIs; columns represent mean ± 95% CI and column width a measure of number of comparisons within each stratum. The solid line represents the level of neutral treatment effect.
The most commonly used prodrugs were GCV (40 comparisons) and 5-FC (24 comparisons, see Appendix S2).

The number of gene therapy doses administered (ranging from 1–7 doses) also accounted for a significant proportion of the between-study heterogeneity. We observed a direct relationship between the number of doses and effect size where up to five doses were given followed by a fall in efficacy where six or seven doses were administered ($\chi^2 = 50.1$, df = 6, $p < 0.0019$; Figure 4B). Intracranial gene therapy delivery was common (328/427 comparisons) and we stratified these into intratumoural, ipsilateral (gene therapy introduced into the same cerebral hemisphere as the tumour), contralateral (opposite hemisphere), coinoculation (tumour and vector inoculated together), pretransfection (glioma cells transfected before tumour inoculation) and unspecified intracerebral. While these groups contain information on both location and time of implantation, we used a single stratification as the variables display collinearity (i.e. coinoculated cells can only be implanted at the same time as the tumour, intratumoural injection requires an established tumour to be present). Of these routes, intratumoural was the most common (226/328), followed by coinoculation (36/328) and pretransfection (31/328). The remaining comparisons, except for one unknown, were systemic—the most commonly used routes being subcutaneous (49/98) and intravenous (32/98). There was no difference in observed effect size between treatments that were delivered centrally and those that had to cross the blood–brain barrier (delivered systemically); however, we did observe significant portion of heterogeneity accounted for by more specific stratification of route of delivery ($\chi^2 = 45.0$, df = 11, $p < 0.0019$; Figure 4C). The routes associated with greatest efficacy were ipsilateral and contralateral central delivery, which were more effective than intratumoural treatment.

Gene therapy was delivered from 1 month before to 1 month after tumour induction. We stratified the data into three groups (before, the same day as, or after the induction of tumour), and the timing of treatment had a significant impact on reported efficacy ($\chi^2 = 13.0$, df = 2, $p < 0.0019$; Figure 4D). Where tumour cells were treated in vitro prior to implantation these were classified as therapy starting on the same day as implantation. The type of control group used did not account for any between-study heterogeneity.

**Influence of factors relating to the animal model used**

Overall, studies using rats reported significantly higher effect sizes (1.71; 95% CI 1.58–1.86; $n = 144$) than mice (1.54; 1.46–1.63; $n = 283$; $\chi^2 = 13.0$, df = 1, $p < 0.0019$; Figure 5A). Experiments were carried out in animals with no reported alterations of their immune status (310/427), athymic animals (92/427) and animals with various forms of severe combined immunodeficiency (SCID; 25/427); studies using SCID animals were associated with greater efficacy ($\chi^2 = 16.2$, df = 2, $p < 0.0019$; Figure 5B). Although the species of origin of the tumour line (mouse, rat, human or unknown) did not account for any between-study heterogeneity, we observed an effect of the tumour line itself ($\chi^2 = 244$, df = 38, $p < 0.0019$; Figure 5C).

Median survival across all control groups was 25 days and across all treatment groups was 40 days. With a median of eight animals in control and treatment groups we estimate that the median powered study in this cohort has only 17% statistical power to detect the median change in median survival. This compares with around 30% in experimental stroke studies (CAMARADES group, data not published), and a convention of seeking power of 80 to 90% in well-conducted clinical trials. As a guide for future investigators in Appendix S5, we present the relationship between statistical power and number needed per group for the above comparison and for a range of median survival ratios that might be sought for in future experiments.

**Thymidine kinase dataset sub-analysis**

We performed a sensitivity analysis for the most common gene therapy paradigm (thymidine kinase with GCV, 30 comparisons using 446 animals). Thymidine kinase gene therapy was associated with a significant increase in median survival (1.99; 95% CI 1.68–2.37) and between-study heterogeneity comparable with the complete dataset ($\chi^2 = 49.9$, df = 29, $p < 0.0019$; $I^2 = 69\%$).

The risk of bias appears to be similar between the two datasets. The median study quality score was again 3 (IQR 2–3.25) and we did not find an association between the number of study quality checklist items scored and efficacy (Figure 6A). Small study bias was suggested with asymmetry in the funnel plot and a positive intercept on Egger regression ($1.56 \pm 1.76; \tau = 6.61, p < 0.001$; Figure 6B and C), but not in “trim and fill” analysis. Again, there were no differences between studies that reported survival data within the text and those where data had to be extracted from a graph, or between the types of control used.

Only one study used more than one dose of gene therapy, only three used a route of delivery other than intracranial inoculation and only three reported efficacy in animals with co-morbidity; these data were not analysed further. There was no effect of the method of gene delivery, the vector used (Figure 6D), the time to delivery, the species used or the species of origin of the tumour cell line.

The tumour line itself did however account for some of the observed heterogeneity in this dataset ($\chi^2 = 40.4$, df = 7, $p < 0.0019$; Figure 5E), as did the approach to determining survival (euthanasia, spontaneous death, unreported) ($\chi^2 = 24.4$, df = 2, $p < 0.0019$), with largest effect observed in studies reporting spontaneous death (median survival ratio 8%) (95% CI 1–15%) higher compared with studies killing animals when they became symptomatic.

Searching for <glioma> and <thymidine kinase> identified only one additional study. In a sensitivity analysis
including data from this study, there were no changes of substance either in the point estimates of efficacy or in any of the conclusions drawn.

Discussion

In this first systematic review and meta-analysis of gene therapy in experimental glioma we show substantial and significant prolongation of median survival across a range of experimental conditions. However, there is a high risk of bias in included studies and we observed substantial heterogeneity; consequently these results should be interpreted with caution. We observed influences on reported efficacy by vector type, control type, delay to treatment, glioma model selection, animal, immune status and the method of determining survival. Further high-quality preclinical investigation developed to better define the impact of the study design characteristics listed above, and in particular for those in which we identified substantial efficacy in conditions that reflect those seen in human disease, may provide promising avenues for clinical trial development.

STUDY QUALITY

Overall the quality of studies was limited; the median number of quality checklist items scored was three of a possible nine (IQR 3–4). Our threshold for significance testing was conservative (Bonferroni correction for 26 stratifications), and while testing for an effect of study quality on treatment efficacy did not reach this significance threshold (p = 0.024), an association is likely. Only 12% of studies reported randomization and less than 4% reported the blinded assessment of outcome. As two thirds of studies met either
three or four checklist items and none met more than seven, we have not been able to ascertain whether high-quality studies give lower estimates of efficacy. This contrasts with findings from other models of neurological disease, where the prevalence of reporting of such factors is higher and where there is evidence that high-quality studies report lower estimates of efficacy.\textsuperscript{15,39,40} We found some evidence of publication bias, including a positive intercept using Egger regression, but the trim and fill approach did not impute any theoretical missing studies. It has been suggested that trim and fill is less powerful than Egger regression,\textsuperscript{36} but the small study effects detected by Egger regression may have other causes, particularly where there is substantial heterogeneity between studies, as is the case.

Figure 6. Thymidine kinase/HSV-1 with ganciclovir (GCV) subset analysis. A. Stratification by aggregated quality score did not account for between-study heterogeneity (p > 0.0019). The grey band represents global 95% confidence intervals (CIs); columns represent mean ± 95% CI and column width a measure of number of comparisons within each stratum. The solid line represents the level of neutral treatment effect. B. Funnel plots showing effect size (x-axis) versus a measure of study precision (y-axis). The dataset appears to be skewed, with imprecise studies generally showing more efficacy than those with larger sample sizes. The solid line represents the line of neutral treatment effect and the dotted line marks the global efficacy estimate. C. Egger regression plot depicting effect size × precision (x-axis) versus precision (y-axis). Regression revealed a positive intercept (p < 0.001). The vertical solid line represents the level of neutral treatment effect; dotted lines represent 95% CI of the regression. D. The vector used to deliver gene therapy was not associated with between-study heterogeneity (p > 0.0019). E. The tumour line used accounted for heterogeneity (p < 0.0019), with RSV-M, BT4C and C6 lines associated with greatest efficacy. However, we observed no difference in efficacy between cells originating from different species (p > 0.0019). The grey bands in D–E represent global 95% CIs; plots represent mean ± 95% CI and the diamond represents a measure of number of comparisons within each stratum. The dotted line represents the level of neutral treatment effect.
Meta-analysis of gene therapy in glioma models

here. Our findings are consistent with the presence of publication bias of the same order as reported in a previous systematic review of temozolomide in experimental glioma.27

STUDY DESIGN FEATURES AFFECTING EXTERNAL VALIDITY

We found no differences between broad categories of gene therapies so we analysed all therapies together, with a sensitivity analysis using only the most commonly used therapy. It is likely that certain individual therapies were substantially more or less effective than the overall estimate but 79% of these were tested in fewer than four experiments (Appendix S3), and in these circumstances meta-analysis contributes little that cannot be gleaned from an examination of primary data. Nonetheless, thymidine kinase was more efficacious than average (median survival ratio 1.99 vs. 1.60). While this supports there being differences in efficacy between treatments there are alternative explanations—for instance differences in the animal and glioma models used. We found differences in efficacy associated with different vector-delivery mechanisms, routes of gene therapy delivery, numbers of doses and delays to treatment. Delivery of gene therapy using stem cells was associated with greatest efficacy in both datasets, and this might relate to more effective delivery to the required site of action, more sustained gene expression or other factors. In the complete dataset, intracranial delivery (rather than intraslesional) and multiple dosing (particularly four or more doses) were most effective. In contrast to the difficulties of transfecting tumours in humans with glioma, we were surprised that, taken together, systemic therapies were as efficacious as those delivered intracranially.42,43 Over 90% of the thymidine kinase studies administered gene therapy intracranially with a single dose—analogous to clinical practice.16,44–46

We also found that features of the disease models used were widely variable and significantly affected the observed efficacy. A total of 40 different glioma cell lines were used, originating from humans, mice and rats. No studies used mice with spontaneously occurring or induced glioma cells and only one reported the use of cells recently extracted from human glioma specimens. Median survival ratios for different cell lines ranged from 1 to 8.56 (median 1.57; IQR 1.34–1.71). This suggests that cell line selection is one of the most important factors for investigators to consider during experimental design. As prominent were the species used and their immune status. Rats and mice were used in both datasets, and roughly one third of the animals used were immune-suppressed; this was associated with greater efficacy. The immune system plays an important role in the body’s response to glioma, so the immune-compromised mouse may not be an ideal model of human disease.

Consistent with the modelling of other neurological conditions, these data suggest that the efficacy of gene therapies in glioma is characterized by heterogeneity in both the disease model used and the treatment delivery. Further, we observed a low prevalence of reporting of measures to reduce the risk of bias (see Appendix S4 for details), possible overstatement of efficacy in studies at risk of bias, and publication bias.15,29,40,47–49

POTENTIAL WEAKNESSES OF OUR APPROACH

There are a number of potential weaknesses to this approach. Foremost, meta-analysis is essentially an observational technique. When we stratify by various study design characteristics and measures of study quality or bias, it may be that there are other unknown differences that are the cause of observed differences. For this reason we have been rigorous in only investigating sources of heterogeneity that we prespecified in a protocol. Our findings demonstrate association rather than causality; the observation that treatments delivered using cellular vectors are more effective than those using viruses or molecular approaches may be due to differences in gene delivery efficiency between these routes, or alternatively it may be that different types of interventions are more suited to different vector systems, and that these interventions differ as a class in their efficacy, or a difference in other study design characteristics shown to be associated with heterogeneity. For this reason our findings should be considered hypothesis-generating only. However, further high-quality preclinical studies can be used directly to test any hypothesis of interest.

Secondly, summarizing a field of research (as we have attempted here) requires by necessity the combination of data from experiments that are, to a greater or lesser extent, dissimilar. In these circumstances, the meaning of a summary estimate of efficacy across a range of studies has limited relevance other than to provide a yardstick of the magnitude of effect that might be expected of an intervention. However, we believe the statistical explanation of the differences between studies, especially in the face of the substantial heterogeneity observed here, is valid and important. This rationale is the basis on which we have deemed it appropriate, corroborated by the evidence that broad groups do not differ in efficacy, to collate all gene therapies into a single analysis—following this, heterogeneity was accounted for by measures of study design rather than the gene therapy paradigm itself. In support of these findings, we ran a separate analysis on the most commonly used gene therapy paradigm, thymidine kinase with GCV; in general we found that the same factors relating to study design and internal and external validity of these experiments had a significant impact on efficacy. Given the presence of such diversity in study design, our findings on study quality, randomization, controlling, experimental design and the consistency of these between the two datasets provide validation of our approach.

Our findings are only as reliable as the data on which they are based, and we have shown that this is likely to be
confounded by poor study quality and by publication bias. However, our search strategy was broad, accepting conference abstracts and publications in languages other than English, so our approach is likely to provide a better summation of what is known than narrative reviews—which are subject to the same potential biases—and the impact of selection bias is likely to have reduced to the minimum possible. We used the term “gene therapy” in our search rather than detailing specific genes so that we might identify the largest number of studies, not just those where the use of that gene was already widely known. The term “gene therapy” may have been unduly restrictive, but searching for “thymidine kinase” and “glioma” in Pubmed—without further limitations—identified only one additional study, inclusion of data from which had no impact on the overall efficacy estimate of efficacy. Finally, we have attempted to minimize false positives in our statistical tests by adjusting for multiple comparisons.

The use of meta-analysis to summarize median survival data is not well established. Because we did not have access to data for individual animals we could not pool hazard ratios as has been suggested for clinical studies, and instead have used methods reported previously, based on the work of Simes et al.,32 as a summary estimate that is comparable with hazard ratio pooling.

**WITHIN THESE LIMITATIONS, ARE THERE ANY IMPLICATIONS FOR FUTURE RESEARCH OR FOR THE DESIGN OF CLINICAL TRIALS?**

In this systematic review and meta-analysis, we have presented substantial evidence that features relating to the risk of bias and experimental design of animal studies significantly affect the observed efficacy of gene therapy for experimental glioma. However, another issue yet to be addressed is that of construct validity; there is evidence from these data that translation of gene therapy from experimental to clinical glioma has failed because the experimental models do not recapitulate human disease.

The optimized conditions that are generally created for animal studies do not recapitulate the heterogeneity of human glioma patients, as these studies are all undertaken on homogeneous rodent populations. While techniques such as meta-analysis seek to counteract this homogeneity, the breadth achieved still does not reflect that of the human population. For example, of these animals, many are immune-compromised, a feature that is uncommon in clinical practice. We have observed a wide variety of glioma models used, but those most commonly selected (GL261, U87 and C6) tend to grow quickly and relatively non-invasively into large discreet spheres, contrasting sharply with irregularly shaped, poorly defined, infiltrative human glioblastoma multiforme tumours.18 While each cell line has certain properties that do relate to human disease—for example extensive capillary networks in U87 models, white matter invasion and low immunogenicity in GL261,54–56 gene mutations in C6 that are comparable to human glioma57—these tumours are appropriate for the study of particular components of glioma biology (such as angiogenesis in U87 or immune therapies in GL261) but perhaps lack the robustness for survival studies preceding translation into clinical trial. The recent emergence of the glioma stem cell hypothesis (implicating a cell with stem-like features in the aetiology and pathogenesis of human glioma) has influenced the design of novel preclinical models but these, to our knowledge, have not yet been adopted into animal studies of gene therapy. Another novel practice is the use of patient-derived xenografts, where animals are inoculated with tumour cells prepared from fresh human surgical specimens rather than cells from established in vitro cultures. These models may be more characteristic of human disease and provide genetic heterogeneity not seen with traditional glioma models; however, we identified only one relevant study using this approach. Finally in animal studies gene transfection rates are evidently high enough to be therapeutically, even when vectors are delivered systemically. Indeed, GL261 tumours are transfected very efficiently by adenoviruses.60 This contrasts with human therapy where transfection rates are low; the blood–brain barrier is obstructive in glioma therapeutics, preventing the use of systemic vector delivery, even when vectors are delivered distal to the ophthalmic artery (Dr Robin Grant, personal communication), as tumour penetration is poor and side effects high. When implanted locally, distribution throughout the tumour is difficult to achieve.43 This may be attributable to differences in the central nervous system anatomy and the host immune system.

The large between-study heterogeneity observed in our data suggests that the efficacy of gene therapy is very variable, depending at least in part on the features we have described and perhaps to a greater degree than is observed in other glioma treatments.27,30 This matches the so-called lack of “robustness” seen with gene therapy in phase II and III clinical trials that has ultimately led to failure.

The statistical power of the experiments included in this meta-analysis was low, and no study reported a formal sample size calculation. Improving the statistical power of gene therapy experiments may help to reduce heterogeneity by reducing the chances of type II (false negative) errors and also the predictive value of positive studies where the prior probability of success was low.62,63 We hope the community finds our guide to statistical power (Appendix S5) helpful in the design of future experiments.

In spite of these limitations, gene therapy treatment for experimental glioma appears to be effective when initiated at later time points, and efficacy was observed against cells of human origin. Both these features are pertinent to successful treatment for human disease, as tumours are only discovered after a period of growth. Gene therapy was effective when given either intracranially or systemically although this does not seem to correlate with clinical
experience. Efficacy appeared to be highest when five doses of the gene therapy were given, but—given the difficulties of systemic administration in humans—it may not be practicable to implant locally more than once. Exploration of the most effective number of treatments was not addressed in any of the included publications and is an important topic for further animal study.

As such, we recommend that future preclinical research focuses on genes ratified in both animal and human glioma cell biology, using orthotopic tumours and intracranial gene delivery over one or more doses; they should ideally use stem-like cancer cells or patient-derived xenografts, or at least provide a rationale for tumour model selection, in non-immune-compromised animals where possible. These studies should be registered, randomized, blind assessment of outcome and provide a sample size calculation in all but hypothesis-generating experiments in accordance with ARRIVE guidelines.64

Conclusions

Gene therapies are associated with substantial increases in median survival in animal models of cerebral glioma, but because of concerns about the internal (study quality), external (study design) and particularly construct (recapitulation of human disease) validity of this literature, these findings should be interpreted with caution. Our analysis suggests that a strategy based on multiple treatments with viral or cellular vectors expressing genes of interest delivered locally, tested in the potentially more relevant tumour models described recently, represents a plausible approach to developing gene therapies for glioma. However, the issues of study quality and construct validity of existing models that we have identified should be addressed in further animal studies if such strategies are to have the best chance of success.

Acknowledgement

We thank Sheila Fisken for her guidance in constructing the literature search.

Conflict of Interest

The authors disclose no potential conflicts of interest for this article.

REFERENCES


**Supporting Information**

Additional Supporting Information may be found in the online version of this article:

Appendix S1. References used in systematic review.
Appendix S2. Study characteristics.
Appendix S3. Collated gene therapies.
Appendix S4. Study quality scores.
Appendix S5. Number of animals per group needed to achieve a set statistical power.